The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1 – 5. RSV is the most common cause of LRTI and the leading cause of hospitalizations in all infants.

Virus 40

Virus Trials Disease Hospitals 40

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. 2] A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Preprint Posted May 5, 2020. [2] Pinto D, Park YJ, Beltramello M, Veesler D, Cortil D, et al.

Virus 52

Virus Vaccine Laboratories Science 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Yet they are the source for many of the viruses that have spilled over into humans with devastating effect, including rabies, Ebola virus, Nipah and Hendra viruses, severe acute respiratory syndrome coronavirus (SARS-CoV), and, likely, SARS-CoV-2. Despite carrying all of these viruses, bats rarely show symptoms of being sick.

Virus 52

Virus Immune Response Clinical Trials Treatment 52